307 Westlake Avenue North
About Juno Therapeutics
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.
August 5, 2013
Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen
CEO and Co-founder: Hans Bishop
Please click here for job opportunities.
Please click here for clinical trial information.
Tweets by Juno
228 articles with Juno Therapeutics
Under the seven-year nonexclusive licensing and supply agreement, Juno has obtained rights to use CTS Dynabeads CD3/CD28 magnetic beads as part of the clinical and commercial manufacturing processes for its current and future CAR T therapies.
STAT reflected back on this year and felt one company stood out for rebounding from tough times.
Juno Therapeutics is now the "cheapest" player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival Bluebird Bio.
Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH
During ASH, Juno also announced that JCAR017 had received the United States Adopted Name (USAN) lisocabtagene maraleucel (liso-cel).
Juno Therapeutics today presented new translational insights on clinical outcomes with its investigational CAR T product candidate JCAR017 at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
Juno Therapeutics and Celgene Corporation Release Additional Data From TRANSCEND Trial of JCAR017 in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
The data were based on a cutoff date of October 9, 2017 and presented by Jeremy Abramson, M.D., of Massachusetts General Hospital, who is a Principal Investigator for the TRANSCEND study.
Juno Therapeutics Signs Licensing Agreements With Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma With Gamma Secretase Inhibition
Gamma secretase is an enzyme that cleaves a set of transmembrane proteins, including BCMA. Multiple publications have shown that treatment with GSIs can increase surface expression of BCMA on tumors, particularly multiple myeloma.
Juno Therapeutics Appoints Ann L. Lee as Executive Vice President of Technical Operations and Patrick Y. Yang as Executive Vice President, Senior Advisor to the CEO
Experienced and accomplished executive additions with proven track records in scaling manufacturing, process development, and CMC portfolio management.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
CAR-T is a hot new area and there are companies hot on Gilead's tail, namely Juno, in a partnership with Celgene, and Novartis.
11/13/2017Noting that biotech stocks have been in "hypergrowth" mode over more than six years, George Budwell, writing for The Motley Fool, looks at three biotech stocks that he would recommend to investors.
Neurotoxicity killed JCAR015 right along with 5 patients in the lead pivotal study, derailing Juno Therapeutics.
The company submitted 15 abstracts to be presented at the upcoming ASH Conference.
Revenue for the three and nine months ended September 30, 2017 was $44.8 million and $85.4 million, compared to $20.8 million and $58.2 million for the three and nine months ended September 30, 2016, respectively.
Juno Therapeutics, Inc. will announce financial results for the third quarter 2017 on Wednesday, November 1, 2017, after the close of U.S.-based financial markets.
Trianni today announced that Juno has entered into a license agreement for The Trianni Mouse, a best-in-class monoclonal antibody discovery platform.
Juno Closes Follow-On Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares